Chemical Nameblinatumomab
Dosage FormInjection (intravenous; 35 mcg)
Drug ClassCD19-directed CD3 T-cell engagers
Approval Year2014


  • For the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
  • For the treatment of adults and children with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Document TitleYearSource
Blincyto (blinatumomab) Prescribing Information.2022Amgen Inc., Thousand Oaks, California
Document TitleYearSource
Systematic review of costs and cost-effectiveness of treatment for relapsed/refractory acute leukemia in children and young adults.2022Expert Review of Hematology
Efficacy and Safety of Blinatumomab for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Systemic Review and Meta-Analysis.2022Clinical Lymphoma Myeloma and Leukemia
Comparing the efficacy of salvage regimens for relapsed/refractory B-cell acute lymphoblastic leukaemia: a systematic review and network meta-analysis.2022Annals of Hematology
A systematic review of blinatumomab in the treatment of acute lymphoblastic leukemia: engaging an old problem with new solutions. 2021Annals of Pharmacotherapy
Commonly reported adverse events associated with pediatric immunotherapy: a systematic review from the Children’s Oncology Group.2021Journal of Pediatric Oncology Nursing
Evidence-based recommendations for nurse monitoring and management of immunotherapy-induced cytokine release syndrome: a systematic review from the Children’s Oncology Group.2021Journal of Pediatric Oncology Nursing
Efficacy of targeted immunotherapy as induction or salvage therapy in acute lymphoblastic leukemia: a systematic review and meta-analysis.2021Technology in Cancer Research & Treatment
Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review)2021Journal of Clinical Medicine
Final clinical guidance report: Blincyto (blinatumomab).2020CADTH
Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: a systemic review and meta-analysis.2019Hematology
Final clinical guidance report: Blincyto (blinatumomab) for Philadelphia chromosome positive acute lymphoblastic leukemia.2019CADTH
Document TitleYearSource
Acute lymphoblastic leukemia in adults.2022Alberta Health Services
Acute Lymphoblastic Leukemia, Version 2.2021.2021Journal of the National Comprehensive Cancer Network
The society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia.2020Journal for Immunotherapy of Cancer
Drug updated on 6/2/2023

More on this drug: Clinical Trials